A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma

Masayoshi Fujii, Katsuyoshi Takata, Shih Sung Chuang, Tomoko Miyata-Takata, Midori Ando, Yasuharu Sato, Tadashi Yoshino

Research output: Contribution to journalArticle

Abstract

The gastrointestinal (GI) tract is the most frequently involved site of extranodal non-Hodgkin lymphomas, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype occurring in the GI tract. TNFAIP3 (A20) genetic alterations were reported to be involved in DLBCL's pathogenesis and a portion of GI-DLBCL cases harbor this alteration. However, the frequency and clinicopathological relations focusing on small and large intestinal DLBCL are unclear. Here, we examined A20 deletion and protein expression and analyzed the clinicopathological features of 52 cases of primary intestinal DLBCL. The most frequently involved site was the ileocecal region (75%), followed by small bowel (13.5%) and large intestine. Immunohistochemically, the ileocecal cases expressed BCL6 (p=0.027) and MUM1 (p=0.0001) significantly more frequently than the small intestinal cases. Six of 47 cases (13%) had A20 heterozygous deletion, whereas all 6 heterozygously deleted cases had detectable A20 protein expression. In summary, A20 abnormality was less prevalent among intestinal DLBCLs with some discordancy between gene deletion and protein expression. Although the A20 alteration status did not affect any clinicopathological characteristics in this series, further studies exploring alterations of A20 and other NF-κB components in primary intestinal DLBCL are needed.

LanguageEnglish
Pages23-30
Number of pages8
JournalActa Medica Okayama
Volume72
Issue number1
Publication statusPublished - Jan 1 2018

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cells
Proteins
Gastrointestinal Tract
Ports and harbors
Genes
Large Intestine
Gene Deletion
Non-Hodgkin's Lymphoma

Keywords

  • A20
  • Cell of origin
  • Heterozygous deletion
  • Primary intestinal diffuse large B-cell lymphoma
  • TNFAIP3

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fujii, M., Takata, K., Chuang, S. S., Miyata-Takata, T., Ando, M., Sato, Y., & Yoshino, T. (2018). A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma. Acta Medica Okayama, 72(1), 23-30.

A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma. / Fujii, Masayoshi; Takata, Katsuyoshi; Chuang, Shih Sung; Miyata-Takata, Tomoko; Ando, Midori; Sato, Yasuharu; Yoshino, Tadashi.

In: Acta Medica Okayama, Vol. 72, No. 1, 01.01.2018, p. 23-30.

Research output: Contribution to journalArticle

Fujii, M, Takata, K, Chuang, SS, Miyata-Takata, T, Ando, M, Sato, Y & Yoshino, T 2018, 'A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma' Acta Medica Okayama, vol. 72, no. 1, pp. 23-30.
Fujii M, Takata K, Chuang SS, Miyata-Takata T, Ando M, Sato Y et al. A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma. Acta Medica Okayama. 2018 Jan 1;72(1):23-30.
Fujii, Masayoshi ; Takata, Katsuyoshi ; Chuang, Shih Sung ; Miyata-Takata, Tomoko ; Ando, Midori ; Sato, Yasuharu ; Yoshino, Tadashi. / A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma. In: Acta Medica Okayama. 2018 ; Vol. 72, No. 1. pp. 23-30.
@article{605d743721cc4944a5259e41040757e3,
title = "A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma",
abstract = "The gastrointestinal (GI) tract is the most frequently involved site of extranodal non-Hodgkin lymphomas, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype occurring in the GI tract. TNFAIP3 (A20) genetic alterations were reported to be involved in DLBCL's pathogenesis and a portion of GI-DLBCL cases harbor this alteration. However, the frequency and clinicopathological relations focusing on small and large intestinal DLBCL are unclear. Here, we examined A20 deletion and protein expression and analyzed the clinicopathological features of 52 cases of primary intestinal DLBCL. The most frequently involved site was the ileocecal region (75{\%}), followed by small bowel (13.5{\%}) and large intestine. Immunohistochemically, the ileocecal cases expressed BCL6 (p=0.027) and MUM1 (p=0.0001) significantly more frequently than the small intestinal cases. Six of 47 cases (13{\%}) had A20 heterozygous deletion, whereas all 6 heterozygously deleted cases had detectable A20 protein expression. In summary, A20 abnormality was less prevalent among intestinal DLBCLs with some discordancy between gene deletion and protein expression. Although the A20 alteration status did not affect any clinicopathological characteristics in this series, further studies exploring alterations of A20 and other NF-κB components in primary intestinal DLBCL are needed.",
keywords = "A20, Cell of origin, Heterozygous deletion, Primary intestinal diffuse large B-cell lymphoma, TNFAIP3",
author = "Masayoshi Fujii and Katsuyoshi Takata and Chuang, {Shih Sung} and Tomoko Miyata-Takata and Midori Ando and Yasuharu Sato and Tadashi Yoshino",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "23--30",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma

AU - Fujii, Masayoshi

AU - Takata, Katsuyoshi

AU - Chuang, Shih Sung

AU - Miyata-Takata, Tomoko

AU - Ando, Midori

AU - Sato, Yasuharu

AU - Yoshino, Tadashi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The gastrointestinal (GI) tract is the most frequently involved site of extranodal non-Hodgkin lymphomas, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype occurring in the GI tract. TNFAIP3 (A20) genetic alterations were reported to be involved in DLBCL's pathogenesis and a portion of GI-DLBCL cases harbor this alteration. However, the frequency and clinicopathological relations focusing on small and large intestinal DLBCL are unclear. Here, we examined A20 deletion and protein expression and analyzed the clinicopathological features of 52 cases of primary intestinal DLBCL. The most frequently involved site was the ileocecal region (75%), followed by small bowel (13.5%) and large intestine. Immunohistochemically, the ileocecal cases expressed BCL6 (p=0.027) and MUM1 (p=0.0001) significantly more frequently than the small intestinal cases. Six of 47 cases (13%) had A20 heterozygous deletion, whereas all 6 heterozygously deleted cases had detectable A20 protein expression. In summary, A20 abnormality was less prevalent among intestinal DLBCLs with some discordancy between gene deletion and protein expression. Although the A20 alteration status did not affect any clinicopathological characteristics in this series, further studies exploring alterations of A20 and other NF-κB components in primary intestinal DLBCL are needed.

AB - The gastrointestinal (GI) tract is the most frequently involved site of extranodal non-Hodgkin lymphomas, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype occurring in the GI tract. TNFAIP3 (A20) genetic alterations were reported to be involved in DLBCL's pathogenesis and a portion of GI-DLBCL cases harbor this alteration. However, the frequency and clinicopathological relations focusing on small and large intestinal DLBCL are unclear. Here, we examined A20 deletion and protein expression and analyzed the clinicopathological features of 52 cases of primary intestinal DLBCL. The most frequently involved site was the ileocecal region (75%), followed by small bowel (13.5%) and large intestine. Immunohistochemically, the ileocecal cases expressed BCL6 (p=0.027) and MUM1 (p=0.0001) significantly more frequently than the small intestinal cases. Six of 47 cases (13%) had A20 heterozygous deletion, whereas all 6 heterozygously deleted cases had detectable A20 protein expression. In summary, A20 abnormality was less prevalent among intestinal DLBCLs with some discordancy between gene deletion and protein expression. Although the A20 alteration status did not affect any clinicopathological characteristics in this series, further studies exploring alterations of A20 and other NF-κB components in primary intestinal DLBCL are needed.

KW - A20

KW - Cell of origin

KW - Heterozygous deletion

KW - Primary intestinal diffuse large B-cell lymphoma

KW - TNFAIP3

UR - http://www.scopus.com/inward/record.url?scp=85042387543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042387543&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 23

EP - 30

JO - Acta Medica Okayama

T2 - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -